<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283361</url>
  </required_header>
  <id_info>
    <org_study_id>05-025</org_study_id>
    <nct_id>NCT00283361</nct_id>
  </id_info>
  <brief_title>ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure</brief_title>
  <official_title>A Phase II,Randomized, Double-Blind, Flexible Dose Study of ZP120 I.V. Infusion as Add-On Therapy in Patients With Acute or Sub-Acute Decompensated Chronic Heart Failure NYHA Class III-IV Treated With Furosemide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zealand Pharma</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to see if the experimental drug ZP120, when given with the&#xD;
      approved drug furosemide to patients with acute or sub-acute heart failure, can reduce the&#xD;
      amount of fluid in the patients' lungs and make breathing easier.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2006</start_date>
  <completion_date>December 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in dyspnea severity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute walk test performance</measure>
  </secondary_outcome>
  <enrollment>130</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZP120</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>I.v. catherization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>6-minutes walk performance</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dyspnea severity assessment</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling for laboratory tests</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ECG</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physical examination</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients, age 18 years or more&#xD;
&#xD;
          2. A diagnosis of acute or subacute decompensated chronic heart failure, either ischemic&#xD;
             or nonischemic, requiring hospitalization, and currently treated with furosemide,&#xD;
             torsemide, or bumetadine, and other evidence based optimal treatment for heart&#xD;
             failure. Patients must have the clinical diagnosis of CHF made at least 3 month prior&#xD;
             to enrollment&#xD;
&#xD;
          3. Ambulatory&#xD;
&#xD;
          4. Objective signs of LVD corresponding to a LVEF &lt; 45%, documented by any accepted&#xD;
             method within the previous 12 months. If documentation is not available within the&#xD;
             required time frame, LVEF must be assessed prior to enrollment&#xD;
&#xD;
          5. a) Worsening heart failure symptoms (current NYHA class III-IV). Patients must&#xD;
             experience worsening of at least one of the symptoms described below at the time of&#xD;
             entry into the study:&#xD;
&#xD;
             Dyspnea Symptoms:&#xD;
&#xD;
               -  Dyspnea (labored or difficult breathing) at rest&#xD;
&#xD;
               -  Worsening dyspnea (labored or difficult breathing) on minimal exertion&#xD;
&#xD;
               -  Worsening orthopnea (difficult breathing except in the upright position)&#xD;
&#xD;
               -  Increased frequency of nocturnal dyspnea (awaken from sleep due to respiratory&#xD;
                  distress)&#xD;
&#xD;
                  b) Clinical evidence of volume overload such as weight gain over previous few&#xD;
                  days, peripheral edema, hepatic congestion with ascites, pulmonary congestion, or&#xD;
                  pleural effusion&#xD;
&#xD;
          6. Females of childbearing potential must have a negative pregnancy test at enrollment. A&#xD;
             female is considered to be of childbearing potential unless she is post-menopausal (no&#xD;
             menses for at least 12 consecutive months) or without a uterus and/or both ovaries&#xD;
&#xD;
          7. Ability to understand and willing to sign Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Incapable of taking the 6-minute walk test due to any condition unrelated to heart&#xD;
             failure, e.g., muscular or skeletal disability&#xD;
&#xD;
          2. Valvular heart disease requiring surgical intervention (during the course of the&#xD;
             study. Patients with heart failure due to or associated with uncorrected primary&#xD;
             valvular disease, malfunctioning artificial heart valve, or uncorrected congenital&#xD;
             heart disease)&#xD;
&#xD;
          3. History of or clinically significant evidence of any severe disease other than heart&#xD;
             failure that preclude participation and complicate the evaluation of study results&#xD;
             from the local laboratory:&#xD;
&#xD;
               -  Hepatic disease (AST, ALT, total bilirubin &gt; 3 times Upper Limit of Normal (ULN),&#xD;
                  renal disease (S-Creatinine &gt; 2.5 mg/dL),&#xD;
&#xD;
               -  Uncontrolled insulin-dependent diabetes mellitus with a history of frequent&#xD;
                  hypoglycemic episodes or frequent hospitalizations for hyperglycemia,&#xD;
&#xD;
               -  Cancer (excluding treated non-melanoma skin cancer)&#xD;
&#xD;
          4. Unstable angina, cardiogenic shock, or acute pulmonary edema requiring any of the&#xD;
             following: Nitroprusside, intravenous nitroglycerin, nesiritide, intravenous inotrope,&#xD;
             or need for endotracheal intubation and mechanical ventilation&#xD;
&#xD;
          5. Acute myocardial infarction and/or myocardial infarction within 30 days (prior to&#xD;
             enrollment) as diagnosed by investigator's evaluation of clinical symptoms, ECG,&#xD;
             and/or biochemical markers of cardiac injury&#xD;
&#xD;
          6. Cardiac arrest (patients with history of cardiac arrest within 12 months unless&#xD;
             precipitated by an event such as an acute myocardial infarction, induction by catheter&#xD;
             placement, severe transient electrolyte abnormality, by an electrophysiology&#xD;
             procedure, or addressed by Automatic Implantable Cardioverter Defibrillator placement.&#xD;
             Patients with increased risk of cardiac arrest, QTc &gt; 450 msec, atrial ventricular&#xD;
             block II or III, etc.)&#xD;
&#xD;
          7. Sustainable VT/VF within 30 days (&gt; 15 seconds long; patients with enrollment ECG&#xD;
             showing ventricular tachycardia or premature ventricular complexes associated with&#xD;
             symptoms, or ventricular tachycardia of ï‚³6 beats)&#xD;
&#xD;
          8. Uncontrolled atrial fibrillation on enrollment ECG with a ventricular rate &gt;120 bpm&#xD;
&#xD;
          9. Cardiac surgery within the last month or acutely required PCI (patients who have&#xD;
             undergone a cardiac revascularization, valvular surgery, or biventricular&#xD;
             resynchronization procedure within 30 days. Patients who have had ventricular&#xD;
             reduction surgery or cardiac myoplasty and patients with mechanical ventricular assist&#xD;
             device)&#xD;
&#xD;
         10. Systolic blood pressure &lt; 90 mmHg and &gt; 200 mmHg&#xD;
&#xD;
         11. Pulmonary embolism or DVT or history of pulmonary embolism or DVT within 6 months&#xD;
             prior to enrollment&#xD;
&#xD;
         12. Severe obstructive or restrictive pulmonary disease, patients with primary pulmonary&#xD;
             hypertension and heart failure secondary to pulmonary disease, and severe pulmonary&#xD;
             infection&#xD;
&#xD;
         13. I.v. vasoactive treatment, e.g. vasodilators, positive inotropic agents, within 24&#xD;
             hours prior to enrollment (see details in Appendix E)&#xD;
&#xD;
         14. Participation in another study evaluating an experimental treatment within the last 30&#xD;
             days which potentially could bias the outcome of this study&#xD;
&#xD;
         15. Previous treatment with ZP120&#xD;
&#xD;
         16. Patients known to abuse or actively abusing alcohol or illicit drugs. Abuse of alcohol&#xD;
             is defined as the usual daily intake of more than 100 grams of ethanol per day, or&#xD;
             more than approximately six 12-ounce bottles of beer, one 750 mL bottle of wine, or&#xD;
             250 mL of 80 proof spirits&#xD;
&#xD;
         17. Inability or unwillingness to provide informed consent&#xD;
&#xD;
         18. BMI outside range of 20-50 kg/m2 (BMI equal to 20 and 50 kg/m2 is accepted)&#xD;
&#xD;
         19. Any other condition or therapy, which in the opinion of the Principal Investigator&#xD;
             would make the patient unsuitable for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LAC-USC Medical Center-Division of Cardiology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center -WLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of CO Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>123456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health First Clinical Research Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami Miller School of Medicine, Jackson Memorial Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital Anderson/Community Clinical Research Center</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Heart Failure Treatment Program</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The International Heart Institute</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryan LGH Heart Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancaster Heart Foundation</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Clinical Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <study_first_submitted>January 25, 2006</study_first_submitted>
  <study_first_submitted_qc>January 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <last_update_submitted>February 27, 2007</last_update_submitted>
  <last_update_submitted_qc>February 27, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

